REQUEST A DEMO
Total
USD $0.00
Search more companies

Glenmark - Pharmaceuticals Ecuador S.A. (Ecuador)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Glenmark - Pharmaceuticals Ecuador S.A. Profile Updated: May 14, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Spanish Download a sample report

Glenmark - Pharmaceuticals Ecuador S.A. is based in Ecuador, with the head office in Quito. It operates in the Pharmaceutical and Medicine Manufacturing industry. The company was established on March 15, 2017. It currently has a total number of 23 (2023) employees. Its’ total assets recorded a negative growth of 6.48%.

Headquarters
Av. Simon Bolivar, Ekopark Bldg. , Floor 703
Quito; Pichincha;

Contact Details: Purchase the Glenmark - Pharmaceuticals Ecuador S.A. report to view the information.

Basic Information
Total Employees:
Purchase the Glenmark - Pharmaceuticals Ecuador S.A. report to view the information.
Outstanding Shares:
Purchase the Glenmark - Pharmaceuticals Ecuador S.A. report to view the information.
Registered Capital:
Purchase the Glenmark - Pharmaceuticals Ecuador S.A. report to view the information.
Incorporation Date:
March 15, 2017
Key Executives
Purchase this report to view the information.
President
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
100%
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Glenmark - Pharmaceuticals Ecuador S.A. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
EBITDA
845.75%
Net Profit (Loss) for the Period
N/A
Total assets
-6.48%
Total equity
-8.61%
Return on Equity (ROE)
N/A
Debt to Equity Ratio
-6.13%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?